{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Plasma&page=48",
    "query": {
      "condition": "Plasma",
      "page": 48
    },
    "page_size": 10
  },
  "pagination": {
    "page": 48,
    "page_size": 10,
    "total_count": 3601,
    "total_pages": 361,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Plasma&page=49&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Plasma&page=47&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T21:59:30.507Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01234974",
      "title": "IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Pasireotide",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2010-12",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2013-01-10",
      "last_synced_at": "2026-11-17T21:59:30.507Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01234974"
    },
    {
      "nct_id": "NCT04484623",
      "title": "Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Belantamab mafodotin",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 302,
      "start_date": "2020-10-01",
      "completion_date": "2029-06-25",
      "has_results": true,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-11-17T21:59:30.507Z",
      "location_count": 5,
      "location_summary": "Tucson, Arizona • Fort Myers, Florida • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04484623"
    },
    {
      "nct_id": "NCT04294862",
      "title": "Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prosthetic Joint Infection"
      ],
      "interventions": [
        {
          "name": "TNP-2092",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TenNor Therapeutics Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2021-03-01",
      "completion_date": "2022-06-29",
      "has_results": false,
      "last_update_posted_date": "2022-10-19",
      "last_synced_at": "2026-11-17T21:59:30.507Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04294862"
    },
    {
      "nct_id": "NCT01885897",
      "title": "IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia (AML)",
        "Acute Lymphoblastic Leukemia (ALL)",
        "Myelodysplastic Syndromes (MDS)",
        "Lymphoma",
        "Myeloma",
        "Chronic Lymphocytic Leukemia (CLL)",
        "Chronic Myelogenous Leukemia (CML)"
      ],
      "interventions": [
        {
          "name": "ALT-803",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2013-11-11",
      "completion_date": "2020-07",
      "has_results": true,
      "last_update_posted_date": "2020-08-12",
      "last_synced_at": "2026-11-17T21:59:30.507Z",
      "location_count": 3,
      "location_summary": "Minneapolis, Minnesota • St Louis, Missouri • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01885897"
    },
    {
      "nct_id": "NCT05623020",
      "title": "A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Elranatamab",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1060,
      "start_date": "2022-11-10",
      "completion_date": "2033-10-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-17T21:59:30.507Z",
      "location_count": 34,
      "location_summary": "Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 21 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05623020"
    },
    {
      "nct_id": "NCT03303924",
      "title": "Study to Determine and Compare Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ETX2514 and sulbactam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Entasis Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2017-08-21",
      "completion_date": "2017-10-26",
      "has_results": false,
      "last_update_posted_date": "2017-11-09",
      "last_synced_at": "2026-11-17T21:59:30.507Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03303924"
    },
    {
      "nct_id": "NCT01811862",
      "title": "Acupuncture for Symptom Control in Hematopoietic Stem Cell Transplantation Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Acupuncture",
          "type": "PROCEDURE"
        },
        {
          "name": "Sham acupuncture",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2013-03",
      "completion_date": "2021-12-10",
      "has_results": false,
      "last_update_posted_date": "2021-12-14",
      "last_synced_at": "2026-11-17T21:59:30.507Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01811862"
    },
    {
      "nct_id": "NCT00482846",
      "title": "Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mucositis",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Palifermin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "autologous peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "quality-of-life assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2007-06",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2014-04-15",
      "last_synced_at": "2026-11-17T21:59:30.507Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00482846"
    },
    {
      "nct_id": "NCT03656068",
      "title": "An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-alcoholic Steatohepatitis",
        "Fatty Liver",
        "Fibrosis, Liver",
        "Compensated Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Nitazoxanide 500mg BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pinnacle Clinical Research, PLLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 21,
      "start_date": "2018-12-04",
      "completion_date": "2020-11-25",
      "has_results": true,
      "last_update_posted_date": "2022-06-30",
      "last_synced_at": "2026-11-17T21:59:30.507Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03656068"
    },
    {
      "nct_id": "NCT02181413",
      "title": "A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Autologous Stem Cell Transplant"
      ],
      "interventions": [
        {
          "name": "Ixazomib Citrate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 656,
      "start_date": "2014-07-16",
      "completion_date": "2023-09-08",
      "has_results": true,
      "last_update_posted_date": "2024-11-19",
      "last_synced_at": "2026-11-17T21:59:30.507Z",
      "location_count": 6,
      "location_summary": "Little Rock, Arkansas • Rochester, Minnesota • The Bronx, New York + 3 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02181413"
    }
  ]
}